Inovio Pharmaceuticals (INO) Research & Development (2010 - 2026)

Inovio Pharmaceuticals has disclosed Research & Development across 17 years of filings, most recently posting $10.8 million for Q2 2026.

• In Q2 2026, Research & Development fell 25.44% year-over-year to $10.8 million; the TTM figure through Jun 2026 stood at $48.5 million (down 22.08% YoY), while the FY2025 annual figure was $54.2 million, down 28.32% from the prior year.
• Research & Development came in at $10.8 million for Q2 2026 at Inovio Pharmaceuticals, down from $14.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $56.5 million in Q2 2022 to a low of $10.3 million in Q4 2025.
• Average Research & Development over 5 years is $23.8 million, with a median of $18.0 million recorded in 2023.
• Year-over-year, Research & Development surged 43.37% in 2022 and sank 59.04% in 2023.
• Over 5 years, Research & Development stood at $42.1 million in 2022, then slumped by 59.04% to $17.3 million in 2023, then decreased by 25.31% to $12.9 million in 2024, then dropped by 20.37% to $10.3 million in 2025, then advanced by 5.51% to $10.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $10.8 million in Q2 2026, $14.1 million in Q1 2026, and $10.3 million in Q4 2025.